Advocacy intelligence hub — real-time data for patient organizations
NAYZILAM: FDA approved
NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient®s usual seizure pattern in patients with epilepsy 12 years of age and older.
AlphaNine: FDA approved
For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Ganciclovir sodium
Roche
AlphaNine
Alpha Therapeutic Corporation